Literature DB >> 981622

Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate.

D L Schaffer, H P Pendergrass.   

Abstract

Patients (219) with prostatic adenocarcinoma were classified on the basis of whether or not their bone scans were positive for metastasis. Acid and alkaline phosphatase determinations and clinical evaluations for bone metastases were reviewed. Of those with proved metastases, 43% had no bone pain, 39% had normal acid phosphatase levels, 23% normal alkaline phosphatase levels, 19% normal levels of both enzymes, and 15% normal enzyme levels without bone pain. Twenty-four per cent of the patients with normal enzyme levels and clinically unsuspected bone metastases had bone scans which proved positive for metastasis; 62% of these had normal radiographs.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 981622     DOI: 10.1148/121.2.431

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  15 in total

1.  A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.

Authors:  David Ulmert; Reza Kaboteh; Josef J Fox; Caroline Savage; Michael J Evans; Hans Lilja; Per-Anders Abrahamsson; Thomas Björk; Axel Gerdtsson; Anders Bjartell; Peter Gjertsson; Peter Höglund; Milan Lomsky; Mattias Ohlsson; Jens Richter; May Sadik; Michael J Morris; Howard I Scher; Karl Sjöstrand; Alice Yu; Madis Suurküla; Lars Edenbrandt; Steven M Larson
Journal:  Eur Urol       Date:  2012-01-27       Impact factor: 20.096

2.  [Radionuclide bone scan in patients with newly diagnosed prostate cancer. Clinical aspects and cost analysis].

Authors:  T Klatte; D Klatte; M Böhm; E P Allhoff
Journal:  Urologe A       Date:  2006-10       Impact factor: 0.639

3.  The diagnostic value of bone scintigraphy in patients with low back pain.

Authors:  H E Schütte; W M Park
Journal:  Skeletal Radiol       Date:  1983       Impact factor: 2.199

Review 4.  The role of skeletal scanning in clinical oncology.

Authors:  J H McKillop; I R McDougall
Journal:  Br Med J       Date:  1980-08-09

5.  The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer.

Authors:  S Ataus; A Citçi; B Alici; A U Onder; K Sönmezoğlu; A Erözenci; V Solok
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

6.  89Strontium therapy of bone metastases of carcinoma of the prostatic gland.

Authors:  H J Correns; M Mebel; K Buchali; D Schnorr; C Seidel; E Mitterlechner
Journal:  Eur J Nucl Med       Date:  1979-02-01

7.  Clinical experience with intra lymphatic administration of 111In-labelled monoclonal antibody PAY 276 for the detection of pelvic nodal metastases in prostatic carcinoma.

Authors:  H H Abdel-Nabi; J A Ortman-Nabi; W See; J Lee; R Ireton; M Boileau; M W Unger; C Halverson
Journal:  Eur J Nucl Med       Date:  1990

8.  [Pharmacological therapy of urogenital cancer: rational routine diagnostic imaging].

Authors:  A Heidenreich; S Krege
Journal:  Urologe A       Date:  2013-11       Impact factor: 0.639

9.  Prostate cancer: trends in mortality and stage-specific incidence rates by racial/ethnic group in Los Angeles County, California (United States).

Authors:  K L Danley; J L Richardson; L Bernstein; B Langholz; R K Ross
Journal:  Cancer Causes Control       Date:  1995-11       Impact factor: 2.506

10.  How significant are serial bone scans in monitoring advanced prostatic cancer?

Authors:  S Tekgül; H Ozen; R Ozyavuz; M Bakkaloğlu; D Remzi
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.